Sunday, November 18, 2018
Redactor's Choice
You are here: Home / Tag: pfizer (page 2)

Tag: pfizer

Pfizer Completes Acquisition of Medivation

Pfizer_logo

“Pfizer and Medivation are now one unified team combining research and resources to combat cancer. This acquisition represents a rare opportunity to expand our business offering with an attractive pipeline and with XTANDI, an important medicine for men with prostate cancer. We welcome our new Medivation colleagues to the team and look forward to continuing the successful partnership with Astellas for XTANDI,” said Albert Bourla, group president, Pfizer Innovative Health. “Given the breadth of Pfizer’s existing oncology portfolio and emerging im... Read More »

Pfizer Completes Acquisition of Medivation

Pfizer_logo

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Medivation, Inc.(NASDAQ: MDVN). As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the shares outstanding and have been accepted for payment under the terms of the tender offer for $81.50 per share in cash, without interest, subject to any required withholding of taxes. In addition, notices of guaranteed delivery have been delivered for 17,659,861 shares of Medivation co... Read More »

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes

Pfizer_logo

Merck and Pfizer plan to submit New Drug Applications to the U.S. Food and Drug Administration for ertugliflozin and two fixed-dose combinations (ertugliflozin plus JANUVIA® (sitagliptin) and ertugliflozin plus metformin) by the end of 2016, with additional regulatory submissions outside of the U.S. to follow in 2017. “It is encouraging to see further data from the VERTIS clinical development program in support of combining ertugliflozin, an SGLT2 inhibitor, with the DPP-4 inhibitor sitagliptin, which was first approved 10 years ago,” said P... Read More »

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer_logo

To listen to the webcast, visit our web site at www.pfizer.com and click on the “2016 Wells Fargo Healthcare Conference” link in the For Investors section located on the lower right-hand corner of that page. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning today. Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com. Contact: Media: Joan Campion, 212-733-2798 or Investors: Ryan Crowe, 212-733-8160 ... Read More »

Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca

Pfizer_logo

Under the terms of the agreement, Pfizer will make an upfront payment of $550 million to AstraZeneca upon the close of the transaction and a deferred payment of $175 million in January 2019. In addition, AstraZeneca is eligible to receive up to $250 million in milestone payments, up to $600 million in sales-related payments, as well as tiered royalties on sales of Zavicefta and ATM-AVI in certain markets. “As we continue to reshape our Essential Health portfolio, we are focusing on areas that further address global public health needs and th... Read More »

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

Pfizer_logo

“These findings underscore the long-term benefits of early intervention with VYNDAQEL for symptomatic patients with TTR-FAP,” said Dr. Kevin W. Williams, Chief Medical Officer, Rare Disease, Pfizer Innovative Health. “This analysis, which is based on the longest prospective evaluation to date of any medication being studied for TTR-FAP, provides health care professionals with important insights into the management of patients with this disease.” TTR-FAP is a rare, genetic, progressive, and irreversible neurodegenerative disease that signific... Read More »

PFIZER AIMS TO BECOME INDUSTRY LEADER IN GENE THERAPY WITH AQUISITION OF BAMBOO THERAPEUTICS, INC.

Pfizer_logo

Pfizer Inc. (NYSE:PFE) today announced that it has acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C., focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system. This acquisition significantly expands Pfizer’s expertise in gene therapy by providing Pfizer with a clinical and several pre-clinical assets that complement the company’s rare disease portfolio, an advanced ... Read More »

Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B

Pfizer_logo

In addition to SPK-9001, Spark Therapeutics previously received breakthrough therapy designation for voretigene neparvovec, which is being developed for the potential treatment of inherited retinal disease (IRD) caused by mutations in the RPE65 gene. “We are extremely pleased to have been granted breakthrough therapy designation for SPK-9001, which has shown early promise in achieving our goal of eliminating the need for regular infusions to control and prevent bleeding episodes in patients with hemophilia B through a potentially one-time, i... Read More »

Pfizer Receives World Health Organization Prequalification for Multi-Dose Vial Presentation of Prevenar 13®

Pfizer_logo

“It is unconscionable that children in developing countries are still falling ill, or dying, by the hundreds of thousands every year from preventable diseases like invasive pneumococcal disease and meningitis,” said Orin Levine, director of the vaccine delivery team at the Bill & Melinda Gates Foundation. “We need a range of tools to save children's lives and welcome advances like this one that help improve our ability to prevent life-threatening invasive pneumococcal disease.” “We are pleased that the WHO has prequalified the MDV presen... Read More »

Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer

Pfizer_logo

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of avelumab* in combination with, and/or as follow-on (maintenance) treatment to, platinum-based chemotherapy in patients with locally advanced or metastatic disease (Stage III or Stage IV) with previously untreated epithelial ovarian cancer. JAVELIN Ovarian 100 is the first Phase III study evaluating the addition of an immune checkpoint inhibitor to standard-of-care in first-line t... Read More »

Scroll To Top